Vaxart gets BARDA approval to start dosing 10,000 participants in Phase 2b COVID vaccine trial

Vaxart, Inc.

BARDA approved initiation of dosing in 10,000-participant Phase 2b trial of oral COVID-19 vaccine.
First patient expected to be dosed in Q2 2025, per CEO Steven Lo.
Trial is double-blind, randomized, comparator-controlled vs approved mRNA COVID-19 vaccine.
Funding under Project NextGen via RRPV Consortium valued at up to $460.7M.
Funding from HHS/ASPR/BARDA under Other Transaction 75A50123D00005.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.